Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTangible Book ValueTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewGenIvf (NIVF) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for NewGenIvf (NIVF) over the last 4 years, with Q3 2025 value amounting to $295.3 billion.

  • NewGenIvf's Cash & Equivalents changed N/A to $295.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $295.3 billion, marking a year-over-year change of. This contributed to the annual value of $457740.0 for FY2024, which is 74603.73% up from last year.
  • NewGenIvf's Cash & Equivalents amounted to $295.3 billion in Q3 2025.
  • NewGenIvf's 5-year Cash & Equivalents high stood at $295.3 billion for Q3 2025, and its period low was $27556.0 during Q4 2022.
  • Its 4-year average for Cash & Equivalents is $59.1 billion, with a median of $457740.0 in 2024.
  • In the last 5 years, NewGenIvf's Cash & Equivalents skyrocketed by 9634.2% in 2023 and then skyrocketed by 74603.73% in 2024.
  • NewGenIvf's Cash & Equivalents (Quarter) stood at $27556.0 in 2022, then surged by 96.34% to $54104.0 in 2023, then skyrocketed by 746.04% to $457740.0 in 2024, then skyrocketed by 64510102.3% to $295.3 billion in 2025.
  • Its Cash & Equivalents stands at $295.3 billion for Q3 2025, versus $1.6 million for Q2 2025 and $457740.0 for Q4 2024.